Tesamorelin + Ipamorelin - 2X

1 Identity

Fixed-ratio two-component article: a 44-residue N-terminally acylated GHRH analog, trans-3-hexenoyl on the alpha-amino group of Tyr1, co-lyophilized with a five-residue synthetic peptide of the GHRP class. At 44 residues the first component sits above the 40-residue line that conventionally divides a peptide from a protein, and that residue count is a property of the molecule rather than of the mixture. Tesamorelin is the active ingredient of an approved United States drug product, marketed as EGRIFTA, EGRIFTA SV and EGRIFTA WR under NDA 022505 held by Theratechnologies Inc., first approved 10 November 2010, with EGRIFTA WR approved 25 March 2025. Each component's full identity lives on its own record in the catalog and is cross-referenced from here rather than restated. and Tesa/Ipa. The designation 2X is a catalog title and states nothing about ratio, counterion or fill.

Sequence

Per component, cross-referenced. Tesamorelin: trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2, 44 residues, all-L, one sulfur in Met27, C-terminally amidated. Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2, five residues. Residues 1 to 29 of the first component are the native GHRH(1-29) sequence, which is the sermorelin sequence, extended by fifteen residues and acylated.

Molecular formula

Per component; a mixture has no combined formula. Tesamorelin C221H366N72O67S free base, the supplied article being the acetate written C221H366N72O67S with x C2H4O2, x approximately 7. Ipamorelin C38H49N9O5 free base, mono-acetate C40H53N9O7. The single sulfur belongs to tesamorelin alone.

Average mass

Per component, on IUPAC 2021 abridged conventional atomic weights: tesamorelin 5,135.856 Da free base, the EGRIFTA WR prescribing information stating 5,135.9 Da for the same entity; ipamorelin 711.868 Da. AT A nominal 10 mg + 10 mg fill, 20 mg total, the 1.0 : 1.0 mass ratio is a molar ratio of 1.00 : 7.21 — 1.94710 against 14.04755 micromol. That is A wide molar imbalance for an equal-mass fill and it follows directly from a sevenfold difference in molecular weight; trade documents describe such fills as balanced and the arithmetic does not.

Monoisotopic mass

Per component. Tesamorelin 5,132.71664 Da neutral, used with a deconvoluted charge envelope rather than a single-ion match. Ipamorelin 711.3857, [M+H]+ 712.3930. Two separations govern identity: the des-acyl 44-mer at -96.058 Da from the intact hexenoyl species, and sermorelin at 3,357.933, the 1-29 core without the extension or the acyl group. A single blend molecular weight is not a chemical fact and is never printed.

Salt / variant note

(1) the des-acyl species at -96.058 Da from intact tesamorelin, which is a degradant and not a variant, and is invisible without accurate mass on a 5 kDa envelope. (2) sermorelin at 3,357.933, the unextended and unacylated 1-29 core — a different molecule that shares the first twenty-nine residues. (3) Modified GRF (1-29) at 3,367.954 and CJC-1295 (DAC:GRF) at 3,647.250, both routinely substituted in this product category. (4) Methionine sulfoxide at +15.995 Da on the 44-mer. (5) Counterion: tesamorelin as the acetate at roughly seven acetate per mole is a large gross-weight correction, and ipamorelin as acetate or trifluoroacetate. (6) Ratio: 2X is a catalog title, and no ratio for this article is standard.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P2 and P3 — panel definitiontogether, as a union rather than the higher of the two, and every method runs on each component separately rather than once on the vial. P2 governs the acylated 44-mer and adds hexenoyl-group integrity and the free-amine des-acyl species to the sheet. P3 governs ipamorelin, whose Aib1, D-2-Nal3 and D-Phe4 put three of five positions outside the proteinogenic set, so the chiral method runs against that component's own expected D-content and never as a pooled figure across the vial

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Published literature exists for each component, is graded on that component's record and is cross-referenced from here rather than restated. The tesamorelin literature is the largest in its category and rests on registrational trials, by identifier: Falutz et al., N Engl J Med 2007;357:2359-2370, PMID 18057338, DOI 10.1056/NEJMoa072375, n=412, 26 weeks; and Falutz et al., J Clin Endocrinol Metab 2010;95:4291-4304, PMID 20554713, DOI 10.1210/jc.2010-0490, a pooled analysis of two phase 3 trials, n=806. The ipamorelin literature is preclinical in substance and comes from a sponsor program that was discontinued. No published study of this fixed two-component combination at any ratio has been identified; that is a statement about the search rather than a finding about the combination. What governs acceptance of a blend lot is therefore the per-component evidence read alongside the measured ratio, not a citation for the combination.

4 Storage & specification

Storage

Co-lyophilized solid held at -20 degrees C plus or minus 5 degrees C, desiccated and protected from light, in amber glass with the headspace displaced with nitrogen and re-blanketed after subdivision; a non-sterile laboratory chemical with no sterility claim. The N-terminal hexenoyl amide is the hydrolysis-sensitive point in solution and the methionine is the oxidation-sensitive point in both the solid and the reconstituted state; the ipamorelin naphthalene ring makes the solid photosensitive. The light and oxygen controls are written against those reasons rather than as housekeeping.

Shelf life

Provisional at 24 months at -20 degrees C plus or minus 5 degrees C, desiccated, from QA release — the interval that applies to an acylated 44-mer acetate co-lyophilized with a pentapeptide acetate — taken as the shorter of the two component intervals, both provisional 24 months, and provisional pending the company's own data. Des-acyl content and methionine sulfoxide are the retest-limiting attributes rather than peptide-backbone degradation.